Immunogenicity Screening Using in Silico Methods: Correlation between T-Cell Epitope Content and Clinical Immunogenicity of Monoclonal Antibodies

Therapeutic Monoclonal Antibodies: From Bench to Clinic

Volumn , Issue , 2009, Pages 417-437

  Hai, Si Han ^a   McMurry, Julie A ^b   Knopf, Paul M ^a,b   Martin, William ^b   De Groot, Anne S ^a,b  

^a BROWN UNIVERSITY   (United States)

^b EpiVax Inc   (United States)

Author keywords

Comparative Td immunogenicity of different monoclonal antibodies; Incorporating T cell immunogenicity screening into development pipeline; T cell epitope prediction EpiMatrix (EpiVax)

Indexed keywords

EID: 84858324486     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9780470485408.ch18     Document Type: Chapter

References (84)

1. Ahlers, J.D., I.M. Belyakov, E.K. Thomas, and J.A. Berzofsky. 2001. High-affinity T helper epitope induces complementary helper and APC polarization, increased CTL, and protection against viral infection. J. Clin. Invest. 108:1677-1685.
2. Alinari, L., R. Lampalombella, L. Andritsos, R.A. Baiocchi, T.S. Lin, and J.C. Byrd. 2007. Alemtuzumab (Campath-1H) in the treatment of chronic lymphocytic leukemia. Oncogene 26:3644-3653.
3. Bian, H., and J. Hammer. 2004. Discovery of promiscuous HLA-II-restricted T cell epitopes with TEPITOPE. Methods 34(4):468-475.
4. Bluestone, J.A., and A.K. Abbas. 2003. Natural versus adaptive regulatory T cells. Nature Rev. Immunol. 3(3):253-257.
5. Bond, K.B., B. Sriwanthana, T.W. Hodge, A.S. De Groot, T.D. Mastro, N.L. Young, N. Promadej, J.D. Altman, K. Limpakarnjanarat, and J.M. McNicholl. 2001. An HLA-directed molecular and bioinformatics approach identifies new HLA-A11 HIV-1 subtype E cytotoxic T lymphocyte epitopes in HIV-1-infected Thais. AIDS Res. Hum. Retroviruses 20:703-717.
6. Carteni, G., R. Fiorentino, L. Vecchione, B. Chiurazzi, and C. Battista. 2007. Panitumumab a novel drug in cancer treatment. Ann. Oncol. Suppl. 6(vi):16-21.
7. Charo, J., M. Sundback, A. Geluk, T. Ottenhoff, and R. Kiessling. 2001. DNA immunization of HLA transgenic mice with a plasmid expressing mycobacterial heat shock protein 65 results in HLA class I-and II-restricted T cell responses that can be augmented by cytokines. Hum. Gene Ther. 12(14):1797-1804.
8. Clark, M. 2001. Antibody humanization: A case of the "Emperor's new clothes"? Immunol. Today 21:397-402.
9. Congia, M., S. Patel, A.P. Cope, S. De Virgiliis, and G. Sonderstrup. 1998. T cell epitopes of insulin defined in HLA-DR4 transgenic mice are derived from preproinsulin and proinsulin. Proc. Natl. Acad. Sci. USA 95(7):3833-3838.
10. Cosimi, A.B. 1981. Treatment of acute renal allograft rejection with OKT3 monoclonal antibody. Transplantation 32(6):535-539.
11. Damschroder, M.M., L. Widjaja, P.S. Gill, V. Krasnoperov, D. Jiang, W.F. Dall'Acqua, and H. Wu. 2007. Framework shuffling of antibodies to reduce immunogenicity and manipulate functional and biophysical properties. Mol. Immunol. 44(11):3049-3060.
12. De Groot, A.S. 2006. Immunomics: Discovering new targets for vaccine and therapeutics. Drug Discovery Today 11:203-209.
13. De Groot, A.S., and J.A. Berzofsky. 2004. From genome to vaccine: New immunoinformatics tools for vaccine design. Methods 34:425-428.
14. De Groot, A.S., A. Bosma, N. Chinai, J. Frost, B.M. Jesdale, M.A. Gonzalez, W. Martin, and C. Saint-Aubin. 2001a. From genome to vaccine: In silico predictions, ex vivo verification. Vaccine 19(31):4385-4395.
15. De Groot, A.S., D.S. Rivera, J.A. McMurry, S. Buus, and W. Martin. 2008. Identification of immunogenic HLA-B7 "achilles' heel" epitopes within highly conserved regions of HIV. Vaccine 26:3059-3071.
16. De Groot, A.S., B.M. Jesdale, E. Szu, J.R. Schafer, R.M. Chicz, and G. Deocampo. 1997. An interactive Web site providing major histocompatibility ligand predictions: Application to HIV research. AIDS Res. Hum. Retroviruses 13:529-5231.
17. De Groot, A.S., P.M. Knopf, and W. Martin. 2005. De-immunization of therapeutic proteins by T-cell epitope modification. Dev. Biol. (Basel) 122:137-160.
18. De Groot, A.S., J. Rayner, and W. Martin. 2003. Modeling the immunogenicity of therapeutic proteins using T cell epitope mapping. Dev. Biol. (Basel) 112:71-80.
19. De Groot, A.S., C. Saint-Aubin, A. Bosma, H. Sbai, J. Rayner, and W. Martin. 2001b. Rapid determination of HLA B*07 ligands from the West Nile virus NY99 genome. Emerg. Infect. Dis. 7(4):706-713.
20. De Groot, A.S., H. Sbai, C. Saint-Aubin, J.A. McMurry, and W. Martin. 2002. Immuno-informatics: Mining genomes for vaccine components. Immunol. Cell. Biol. 80:255-269.
21. Depil, S., G. Angyalosi, O. Morales, M. Delacre, N. Delhem, V. Francois, B. Georges, J. Hammer, B. Maillere, C. Auriault, and V. Pancre. 2006. Peptide-binding assays and HLA II transgenic Abeta degrees mice are consistent and complementary tools for identifying HLA II-restricted peptides. Vaccine 24:2225-2259.
22. Dong, Y., S. Demaria, X. Sun, F.R. Santori, B.M. Jesdale, A.S. De Groot, W.N. Rom, and Y. Bushkin. 2004. HLA-A2-restricted CD8+-cytotoxic-T cell responses to novel epitopes in Mycobacterium tuberculosis superoxide dismutase, alanine dehydrogenase, and glutamine synthetase. Infect. Immun. 72:2412-2415.
23. Dumont, F.J. 2001. Alemtuzuman (Millenium/ILEX). Curr. Opin. Investig. Drugs 2(1):139-160.
24. Einfeld, D.A., J.P. Brown, M.A. Valentine, E.A. Clark, and J.A. Ledbetter. 1988. Molecular cloning of the human B cell CD20 receptor predicts a hydrophobic protein with multiple transmembrane domains. EMBO J. 7(3):711-717.
25. Eyerman, M.C., and L. Wysocki. 1994. T cell recognition of somatically-generated Ab diversity. J. Immunol. 152:1569-1577.
26. Frenken, L.G., R.H. van der Linden, P.W. Hermans, J.W. Jos, R.C. Ruuls, B. de Geus, and C.T. Verrips. 2000. Isolation of antigen specific llama VHH antibody fragments and their high level secretion by Saccharomyces cerevisiae, J. Biotechnol. 78(1):11-21.
27. Gelder, C.M., R. Lambkin, K.W. Hart, D. Fleming, O.M. Williams, M. Bunce, K.I. Welsh, S.E. Marshall, and J. Oxford. 2002. Associations between human leukocyte antigens and nonresponsiveness to influenza vaccine. J. Infect. Dis. 185:114-117.
28. Gill, D.S., and N.K. Damle. 2006. Biopharmaceutical drug discovery using novel protein scaffolds. Curr. Opin. Biotechnol. 17(6):653-658.
29. Gupta, S., S.R. Indelicato, V. Jethwa, T. Kawabata, M. Kelley, A.R. Mire-Sluis, S.M. Richards, B. Rup, E. Shores, S.J. Swanon, and E. Wakshull. 2007. Recommendations for the design, optimization, and qualification of cell-based assays used for the detection of neutralizing antibody responses elicited to biological therapeutics. J. Immunol. Methods 32:11-18.
30. Hacker, H. 2000. Signal transduction pathways activated by CpG-DNA. Curr. Top. Microbiol. Immunol. 247:277-292.
31. Hay, C., M. Recht, M. Carcao, and B. Reipert. 2006. Current and future approaches to inhibitor management and aversion. Semin. Thromb. Hemost. 32(Suppl 2):15-21.
32. TM), Association for Immunotherapy of Cancer: Cancer Immunotherapy-2nd Annual Meeting Mainz, Germany. 6-7 May 2004. Cancer Cell International 4:S20.
33. Hill, A.V., A. Jepson, M. Plebanski, and S.C. Gilbert. 1997. Genetic analysis of host-parasite coevolution in human malaria. Philos. Trans. R. Soc. London B Biol. Sci. 352:1317-1325.
34. Hwang, W.Y., and J. Foote. 2005. Immunogenicity of engineered antibodies. Methods 36:3-10.
35. Inaba, H., W. Martin, A.S. De Groot, S. Qin, and L.J. De Groot. 2006. Thyrotropin receptor epitopes and their relation to histocompatibility leukocyte antigen-DR molecules in Grave's disease. J. Clin. Endocrinol. Metab. 91:2286-2294.
36. Ishioka, G.Y., J. Fikes, G. Hermanson, B. Livingston, C. Crimi, M. Qin, M.F. del Guercio, C. Oseroff, C. Dahlberg, J. Alexander, R.W. Chesnut, and A Sette. 1999. Utilization of MHC class I transgenic mice for development of minigene DNAvaccines encoding multiple HLA-restricted CTL epitopes. J. Immunol. 162(7):3915-3925.
37. Jakobovits, A., R.G. Amado, X. Yang, L. Roskos, and G. Schwab. 2007. From XenoMouse technology to panitu-mumab, the first fully human antibody product from transgenic mice. Nature Biotechnol. 25(10):1134-1143.
38. Jakobovits, A., G.J. Vergara, J.L. Kennedy, J.F. Hales, R.P. McGuinness, D.E. Casentini-Borocz, D.G. Brenner, and G.R. Otten. 1993. Analysis of homozygous mutant chimeric mouse: Deletion of the immunoglobulin heavy-chain joining region blocks B-cell development and antibody production. Proc. Natl. Acad. Sci. USA 90:2551-2555.
39. Jiang, X., and K.D. Moudgil. 2006. The unveiling of hidden T-cell determinants of a native antigen by defined mediators of inflammation: Implications for the pathogenesis of autoimmunity. Scand. J. Immunol. 63:338-346.
40. Jones, T.D., M. Hanlon, B.J. Smith, C.T. Heise, P.D. Nayee, D.A. Sanders, A. Hamilton, C. Sweet, E. Unitt, G. Alexander, K.M. Lo, S.D. Gillies, F.J. Carr, and M.P. Baker. 2004. The development of a modified human IFN-alpha2 linked to the Fc portion of human IgG1 as a novel potential therapeutic for the treatment of hepatitis C infection. J. Interferon Cytokine Res. 24(9):560-572.
41. Kappler, J.W., N. Roehm, and P. Marrack. 1987. T-cell tolerance by clonal elimination in the thymus. Cell 49:273-280.
42. Kast, W.M., R.M. Brandt, J. Sidney, J.W. Drijfhout, R.T. Kubo, H.M. Grey, C.J. Melief, and A. Sette. 1994. Role of HLA-A motifs in identification of potential CTL epitopes in human papillomavirus type 16 E6 and E7 proteins. J. Immunol. 152:3904-3912.
43. Klitgaard, J.L., V.W. Coljee, P.S. Andersen, L.K. Rasmussen, L.S. Nielsen, J.S. Haurum, and S. Bregenholt. 2006. Reduced susceptibility of recombinant polyclonal antibodies to inhibitory anti-variable domain antibody responses. J. Immunol. 177(6):3782-3790.
44. Kohler, G., and C. Milstein. 1976. Derivation of specific antibody-producing tissue culture and tumor lines by cell fusion. Eur. J. Immunol. 6(7):511-519.
45. Koita, O.A., D. Dabitao, I. Mahamadou, M. Tall, S. Dao, A. Tounkara, H. Guiteye, C. Noumsi, O. Thiero, M. Kone, D. Rivera, J.A. McMurry, W. Martin, and A.S. De Groot. 2006. Confirmation of immunogenic consensus sequence HIV-1 T cell epitopes in Bamako, Mali and Providence, Rhode Island. Hum. Vaccin. 2(3):119-128.
46. Kong, Y.C., L.C. Lomo, R.W. Motte, A.A. Giraldo, J. Baisch, G. Strauss, G.J. Hammerling, and C.S. David. 1996. HLA-DRB1 polymorphism determines susceptibility to autoimmune thyroiditis in transgenic mice: Definitive association with HLA-DRBT0301 (DR3) gene. J. Exp. Med. 184:1167-1172.
47. Kooster, R., B.T. Maassen, J.C. Stam, P.W. Hermans, M.R. Ten Haaft, F.J. Detmers, H.J. de Haard, J., Post, and C. Theo Verrips. 2007. Improved anti-IgG and HAS affinity ligands: Clinical application of VHH antibody technology. J. Immunol. Methods 324(1-2):1-12.
48. Koren, E., A.S. De Groot, V. Jawa, K.D. Beck, D. Rivera, L. Li, D. Mytych, M. Kosec, D. Weeraratne, S. Swanson, and W. Martin. 2007. Clinical validation of the "in silico" prediction of immunogenicity of a human recombi-nant therapeutic protein. Clin. Immunol. 124(1):25-32.
49. Koren, E., L.A. Zuckerman, and A.R. Mire-Sluis. 2002. Immune responses to therapeutic proteins in humans: Clinical significance, assessment and prediction. Curr. Pharm. Biotechnol. 3:349-360.
50. Livingston, B.D., M. Newman, C. Crimi, D. McKinney, R.W. Chesnut, and A. Sette. 2001. Optimization of epitope processing enhances immunogenicity of multiepitope DNA vaccines. Vaccine 19(32):4652-4660.
51. Man, S., M.H. Newberg, V.L. Crotzer, C.J. Luckey, N.S. Williams, Y. Chen, E.L. Huczko, J.P. Ridge, and V.H. Engelhard. 1995. Definition of a human T-cell epitope from influenza A non-structural protein 1 using HLA-A2.1 transgenic mice. Int. Immunol. 7(4):597-605.
52. McMurry, J.A., S.H. Gregory, L. Moise, D. Rivera, S. Buus, and A.S. De Groot. 2007a. Diversity of Francisella tularensis Schu4 antigens recognized by T lymphocytes after natural infections in humans: Identification of candidate epitopes for inclusion in a rationally designed tularemia vaccine. Vaccine 25(16):3179-3191.
53. McMurry, J.A., S. Kimball, J.H. Lee, D. Rivera, W. Martin, D.B. Weiner, M. Kutzler, D.R. Sherman, H. Kornfeld, and A.S. De Groot. 2007b. Epitope-driven TB vaccine development: A streamlined approach using immuno-informatics, ELISpot assays and HLA transgenic mice. Curr. Mol. Med. 7(4):351-363.
54. McMurry, J., H. Sbai, M.L. Gennaro, E.J. Carter, W. Martin, and A.S. De Groot. 2005. Analyzing Mycobacterium tuberculosis proteomes for candidate vaccine epitopes. Tuberculosis (Edinburgh) 85:95-105.
55. Mire-Sluis, A.R., Y.C. Barrett, V. Devanarayan, E. Koren, H. Liu, M. Maia, T. Parish, G. Scott, G. Shankar, E. Shores, S.J. Swanson, G. Taniguchi, D. Wierda, and L.A. Zuckerman. 2004. Recommendations for the design and optimization of immunoassays used in the detection of host antibodies against biotechnology products. J. Immunol. Methods 289:1-16.
56. Moutaftsi, M., B. Peters, V. Pasquetto, D.C. Tscharke, J. Sidney, H.H. Bui, H. Grey, and A. Sette. 2006. A consensus epitope prediction approach identifies the breadth of murine T(CD8+)-cell responses to vaccinia virus. Nature Biotechnol. 24(7):817-819.
57. Mullbacher, A. 1992. Viral escape from immune recognition: Multiple strategies of adenoviruses. Immunol. Cell. Biol. 70:59-63.
58. Muyldermans, S. 2001. Single domain camel antibodies: Current status. J. Biotechnol. 74:277.
59. Oling, V., J. Marttila, J. Ilonen, W.W. Kwok, G. Nepom, M. Knip, O. Simell, and H. Reijonen. 2006. GAD65-and proinsulin-specific CD4+ T-cells detected by MHC class II tetramers in peripheral blood of type 1 diabetes patients and at-risk subjects. J. Autoimmun. 27(1):69.
60. Page, K.R., A.L. Scott, and Y.C. Manabe. 2006. The expanding realm of heterologous immunity: Friendor foe? Cell Microbiol. 8:185-196.
61. Pan, S., T. Trejo, J. Hansen, M. Smart, and C.S. David. 1998. HLA-DR4 (DRB1O401) transgenic mice expressing an altered CD4-binding site: Specificity and magnitude of DR4-restricted T-cell response. J. Immunol. 161(6):2925-2929.
62. Piro, L.D., C.A. White, A.J. Grillo-Lopez, N. Janakiraman, A. Saven, T.M. Beck, C. Varns, S. Shuey, M. Czuczman, J.W. Lynch, J.E. Kolitz, and V. Jain. 1999. Extended Rituximab (anti-CD20 monoclonal antibody) therapy for relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma. Ann. Oncol. 10(6):655-661.
63. Pollack, P., and J.R. Groothuis. 2002. Development and use of palivizumab (Synagis): A passive immunoprophy-lactc agent for RSV. J. Infect. Chemother. 8:201-216.
64. Queen, C., W.P. Schneider, H.E. Selick, P.W. Payne, N.F. Landolfi, F.J. Duncan, N.M. Avdalovic, M. Levitt, R.P. Junghans, and T.A. Waldmann. 1989. A humanized antibody that binds to the interleukin 2 receptor. Proc. Natl. Acad. Sci. USA 86:10029-10033.
65. Rammensee, H., J. Bachmann, N.P. Emmerich, O.A. Bachor, and S. Stevanovic. 1999. SYFPEITHI: Database for MHC ligands and peptide motifs. Immunogenetics 50(3-4):213-219.
66. Ramos-Casals, M., P. Brito-Zeron, S. Munoz, N. Soria, D. Galiana, L. Bertolaccini, M.J. Cuadrado, and M.A. Khamashta. 2007. Autoimmune diseases induced by TNF-targeted therapies: Analysis of 233 cases. Medicine (Baltimore) 86(4):242-251.
67. Reveille, J.D. 2006. The genetic basis of autoantibody production. Autoimmun. Rev. 5(6):389-398.
68. Riechmann, L., M. Clark, H. Waldmann, and G. Winter. 1988. Reshaping human antibodies for therapy. Nature 332:323-327.
69. Scanlan, M.J., and D. Jager. 2001. Challengesto the development of antigen-specific breast cancer vaccines. Breast CancerRes. 3:95-98.
70. Schneider, C., and M.H. Van Regenmortel. 1992. Immunogenicity of free synthetic peptides corresponding to T helper epitopes of the influenza HA 1 subunit. Induction of virus cross reacting CD4+ T lymphocytes in mice. Arch. Virol. 125:103-119.
71. Scott, A.M., F.T. Lee, R. Jones, W. Hopkins, D. MacGregor, J.S. Cebon, A. Hannah, G.U.P. Chong, A. Papenfuss, A. Rigopoulos, S. Sturrock, R. Murphy, V. Wirth, C. Murone, F.E. Smyth, S. Knight, S. Welt, G. Ritter, E. Richards, E.C. Nice, A.W. Burgess, and L.J. Old. 2005. Phase I study of anticolon cancer humanized antibody A33: Biodistribution, pharmacokinetics and quantitative tumor uptake. Clin. Cancer Res. 11(13):4810-4817.
72. Shirai, M., T. Arichi, M. Nishioka, T. Nomura, K. Ikeda, K. Kawanishi, V.H. Engelhard, S.M. Feinstone, and J.A. Berzofsky. 1995. CTL responses of HLA-A2.1-transgenic mice specific for hepatitis C viral peptides predict epitopes for CTL of humans carrying HLA-A2.1. J. Immunol. 154(6):2733-2742.
73. Southwood, S., J. Sidney, A. Kondo, M.F. Del Guercio, E. Appella, S. Hoffman, R.T. Kubo, R.W. Chesnut, H.M. Grey, and A. Sette. 1998. Several common HLA-DR types share largely overlapping peptide binding repertoires. J. Immunol. 160(7):3363-3373.
74. Staelens, S., J. Desmet, T.H. Ngo, S. Vauterin, I. Pareyn, P. Barbeaux, I. Van Rompaey, J.M. Stassen, H. Deckmyn, and K. Vanhoorelbeke. 2006. Humanization by variable domain resurfacing and grafting on a human IgG4, using a new approach for determination of non-human like surface accessible framework residues based on homology modelling of variable domain. Mol. Immunol. 43:1243-1257.
75. Steere, A.C., W. Klitz, E.E. Drouin, B.A. Falk, W.W. Kwok, G.T. Nepom, and L.A. Baxter-Lowe. 2006. Antibiotic-refractory Lyme arthritis is associated with HLA-DR molecules that bind a Borrelia burgdorferi peptide. J. Exp. Med. 203(4):961-971.
76. Szolar, O.H., S. Stranner, I. Zinoecker, G.C. Mudde, G. Himmler, G. Waxenecker, and A. Nechansky. 2006. Qualification and application of a surface plasmon resonance-based assay for monitoring potential HAHA responses induced after passive administration of a humanized anti Lewis-Y antibody. J. Pharm. Biomed. Anal. 41(4):1347-1353.
77. Tangri, S., B.R. Mothe, J. Eisenbraun, J. Sidney, S. Southwood, K. Briggs, J. Zinckgraf, P. Bilsel, M. Newman, R. Chesnut, C. Licalsi, and A. Sette. 2005. Rationally engineered therapeutic proteins with reduced immuno-genicity. J. Immunol. 174:3187-3196.
78. Test, S.T., J. Mitsuyoshi, C.C. Connolly, and A.H. Lucas. 2001. Increased immunogenicity and induction of class switching by conjugation of complement C3d to pneumococcal serotype 14 capsular polysaccharide. Infect. Immun. 69(5):3031-3040.
79. Van Walle, I., Y. Gansemans, P.W. Parren, P. Stas, and I. Lasters 2007. Immunogenicity screening in protein drug development. Expert Opin. Biol. Ther. 7:405-418.
80. Verheesen, P., M.R. Ten Haaft, N. Lindner, C.T. Verrips, and J.J. De Haard. 2003. Beneficial properties of singledomain antibody fragments for application in immunoaffinity purification and immuno-perfusion chromato-graphy. Biochem. Biophys. Acta 1624:21.
81. Vossen, M.T., E.M. Westerhout, C. Soderberg-Naucler, and E.J. Wiertz. 2002. Viral immune evasion: A masterpiece of evolution. Immunogenetics 54:527-542.
82. Yeung, P., J. Chang, J. Miller, C. Barnett, M. Stickler, and F.A. Harding. 2004. Elimination of an immunodominant CD4 T-cell epitope in human IFN-does not result in an in vivo response directed at the subdominant epitope. J. Immunol. 172(11):6658-6665.
83. Young, J. 2002. Development of a potent respiratory syncytial virus-specific monoclonal antibody for the prevention of serious lower respiratory tract disease in infants. Respir. Med. Suppl. B S31-S35.
84. Zubler, R.H. 2001. Naive and memory B cells in T-cell-dependent and T-independent responses. Springer Seminars Immunopathol. 23:405-419.